CureDuchenne Ventures is now funding and collaborating in Entrada Therapeutics‘ Duchenne program, as was announced recently as part of Entrada’s latest financing from a group of investors.

Entrada, a biotechnology company based in Boston, will use the funding from CureDuchenne to advance its lead Duchenne exon-skipping oligonucleotide program to the clinic.

“CureDuchenne continues to believe in the promise of safe and effective exon-skipping therapies to restore dystrophin in cardiac and skeletal muscle, and the importance of having a robust pipeline with multiple ‘shots on goal.’ We are thrilled that Entrada’s team of dedicated leaders have set their sights on Duchenne as their lead indication, and look forward to how their program progresses.” 

— Debra Miller, Founder and CEO of CureDuchenne

[Source: CureDuchenne]